Cargando…
BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without dr...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560979/ https://www.ncbi.nlm.nih.gov/pubmed/34696543 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29 |
_version_ | 1784593036126191616 |
---|---|
collection | PubMed |
description | With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without driver gene mutation, which is far from meeting the clinical needs. In recent years, targeted therapy for NSCLC patients with BRAF V600E mutations has shown good efficacy when we are still exploring the better targeted therapies for other BRAF-mutated subtypes. Immunotherapy also showed positive antitumor activity in V600E and non-V600E subtypes of BRAF-mutated NSCLC. This article reviewed the progress of immunological and targeted therapy for patients with BRAF-mutated NSCLC. |
format | Online Article Text |
id | pubmed-8560979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85609792021-11-10 BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without driver gene mutation, which is far from meeting the clinical needs. In recent years, targeted therapy for NSCLC patients with BRAF V600E mutations has shown good efficacy when we are still exploring the better targeted therapies for other BRAF-mutated subtypes. Immunotherapy also showed positive antitumor activity in V600E and non-V600E subtypes of BRAF-mutated NSCLC. This article reviewed the progress of immunological and targeted therapy for patients with BRAF-mutated NSCLC. 中国肺癌杂志编辑部 2021-10-20 /pmc/articles/PMC8560979/ /pubmed/34696543 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 |
title | BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 |
title_full | BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 |
title_fullStr | BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 |
title_full_unstemmed | BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 |
title_short | BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 |
title_sort | braf突变晚期nsclc的靶向和免疫治疗研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560979/ https://www.ncbi.nlm.nih.gov/pubmed/34696543 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29 |
work_keys_str_mv | AT braftūbiànwǎnqīnsclcdebǎxiànghémiǎnyìzhìliáoyánjiūjìnzhǎn AT braftūbiànwǎnqīnsclcdebǎxiànghémiǎnyìzhìliáoyánjiūjìnzhǎn AT braftūbiànwǎnqīnsclcdebǎxiànghémiǎnyìzhìliáoyánjiūjìnzhǎn |